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ABSTRACT  
Aims:    To investigate the cost-effectiveness of up to £400 worth of financial incentives for smoking 
cessation in pregnancy as an adjunct to routine healthcare.Design: Cost-effectiveness analysis based 
on a phase II RCT and a cost-utility analysis using a lifetime Markov model. Setting: The RCT was 
undertaken in Glasgow, Scotland. The economic analysis is undertaken from the UK NHS 
perspective.  Participants:  612 pregnant women randomised to receive usual cessation support +/- 
financial incentives of up to £400 vouchers ($609 USD), contingent on smoking cessation.  
Measurements: Comparison of usual support and incentive interventions in terms of cotinine 
validate quitters, Quality Adjusted Life Years (QALYs)and direct costs to the NHS. Findings: The 
incremental cost per quitter at 34-38 weeks pregnant was £1127 ($1716).This is similar to the 
standard look-up value derived from Stapleton & Wests published ICER tables (72), £1390 per 
quitter, by looking-up the CPIT trial incremental cost (£157) and incremental 6 month quit outcome 
(0.14). The lifetime model resulted in an incremental cost of £17 (95% CI: -£93, £107) and a gain of 
0.04 QALYs (95% CI: -0.058, 0.145), giving an ICER of £482/QALY ($734/QALY). Probabilistic 
sensitivity analysis indicates uncertainty in these results, particularly regarding relapse after birth. 
The expected value of perfect information was £30 million (at a willingness to pay of £30,000/QALY), 
so given current uncertainty, additional research is potentially worthwhile. Conclusion: Financial 
incentives for smoking cessation in pregnancy are highly cost-effective, with  an incremental cost per 
QALY of £482, which is well below recommended decision thresholds.   
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INTRODUCTION 
Smoking during pregnancy is the leading preventable cause of morbidity and death amongst women 
and their babies (1;2), costing between £20-£87 million per annum in the UK (3), and over 
$367million (4) (£241million1) in the USA.    Smoking in pregnancy accounts for up to 30% of low-
birth weight babies and up to 14% of pre-term deliveries per annum and is associated with increased 
risks for ectopic pregnancy, premature rupture of membranes, stillbirth, low birth weight, and 
congenital anomalies such as cleft lip (6).   
Despite these risks, 10 to 20% of pregnant women in Europe continue to smoke during pregnancy 
(7).  In Scotland 18% of pregnant women smoke(8), and only 20% of them manage to quit during 
their pregnancy (9). A range of effective cessation services exist to support pregnant smokers 
(10;11), however, engagement with these services is poor as are successful quit attempts (9;12). 
Financial incentives have been proposed as a  valuable addition to the behaviour change toolkit 
(13;14), with a wide body of experimental evidence supporting their success in abstinence from a 
range of addictive substances (15-19), including nicotine   (20;21). In 2010 NICE reported there is 
little evidence to support use of financial incentives in a routine smoking cessation setting (11),while 
a Cochrane review (22) found financial incentives to be the ‘single most effective intervention’ for 
smoking cessation during pregnancy,  based on four small trials conducted in the USA.  Since then 
further trials have been published in support of financial incentives (23;24) (20;25-27).  While the 
efficacy evidence on financial incentives is growing, as yet there has been little economic analysis of 
their value in addition to existing public health services, and no cost-effectiveness analyses on their 
value in smoking cessation during pregnancy.   The healthcare system in the UK is a publicly funded 
National Health Service (NHS),  primarily funded through taxes providing comprehensive healthcare 
to all UK residents; most of which is free at the point of use. A collectively financed healthcare 
system such as the NHS cannot afford to fund every new clinical and public health intervention, and 
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therefore choices need to be made about funding allocation (28;29), aided by the recommended UK 
cost-effectiveness threshold of £20,000/QALY(30;). Indeed, many countries now require economic 
evidence prior to reimbursement (31). If financial incentives to aid smoking cessation are to be 
considered as an option in the UK and other high income countries, then cost-effectiveness analyses 
are integral to policy-making considerations.  The current  guidance for smoking cessation in 
pregnancy highlights the need for economic evidence on financial incentives for pregnant smokers 
(11).  Therefore, this paper reports on an economic evaluation undertaken as part of a phase II 
randomised controlled trial (ISRCTN 87508788) (32;33) of 612 pregnant women in Glasgow, 
Scotland; to assess the cost-effectiveness of the offer of up to £400 of shopping vouchers in addition 
to routine care to help pregnant smokers quit.  To our knowledge this is the first cost-effectiveness 
analysis of financial incentives for smoking cessation in pregnant women.  
  METHODS 
This economic evaluation was undertaken alongside the Cessation in Pregnancy Incentives Trial 
(CPIT) (ISRCTN 87508788); which was a large single centre, single blinded, randomised, controlled 
parallel group trial, undertaken in Glasgow, Scotland. The trial recruited 612 (609 after three 
patients withdrew consent post randomisation) self-reported smokers who had a carbon monoxide 
(CO) reading of at least 7ppm at maternity booking, were aged 16 years and over, less than 24 weeks 
pregnant and resident in NHS Greater Glasgow and Clyde (GGC), following the published CPIT trial 
protocol (32). The control arm (n=303) received routine care consisting of routine referral to the NHS 
GGC Stop Smoking Services (SSS) which offer specialist pregnancy cessation advice in a one hour 
face-to-face appointment, followed by four weekly telephone support calls and ‘free to the user’ 
Nicotine Replacement Therapy (NRT) via local pharmacies for 10 weeks.  The intervention arm 
(n=306) received routine care, as described above, with the addition of up to £400 vouchers 
(Love2shop) for engaging with the SSS (£50 for attending the first face-to-face appointment and 
setting a quit date) and for quitting during pregnancy (£50 for achieving a 4-week CO validated quit, 
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£100 for achieving a 12 weeks CO validated quit; and £200 for a CO validated quit at 34-38 weeks 
pregnancy).  Further details of the intervention, level and contingency of the incentives, 
randomisation, methods and outcomes for the trial are reported elsewhere (33;34).   
The cost-effectiveness analysis was undertaken from the UK NHS perspective for cost year 2013, 
adhering to good practice guidelines (30;35). The analysis was undertaken in two parts: a within-trial 
analysis which utilised data on resource use  and quit outcomes to report the incremental cost per 
late pregnancy quitter; followed by a lifetime analysis which adapted a previously published 
probabilistic decision analytic model (36;37) to assess the incremental cost per quality adjusted life 
year (QALY) gained. The analyses are described below, with further details provided in the 
supplementary report. 
Within trial analysis 
The primary effectiveness endpoint for the trial was the number of cotinine validated quitters at 34-
38 weeks pregnancy. The analysis used an intention-to-treat approach and all clients who were lost 
to follow-up were considered to have relapsed (33). 
The direct healthcare costs for each arm of the trial are attributed to three areas: cessation support 
(face-to-face and telephone), NRT and financial incentives (Table 1).  Unit cost information (Table 2) 
was combined with the trial resource use data and the mean cost per client in each arm was 
estimated (35). Patient level data on resource use included: duration of first contact (face-to-face 
support and/or first phone contact); number and duration of support calls post quit-date; number of 
clients accepting a four week supply of NRT at week 1, and week 5; and in the intervention arm, the 
number of clients receiving financial incentives at the pre-specified time points. Administration costs 
such as postage and packaging for vouchers (sent via special delivery) were included. Unit cost 
information was taken from routine sources such as the British National Formulary (38), the Personal 
Social Services Research Unit (39) and from the trial sources (value of the vouchers, postage and 
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packaging charges).  Costs are in UK pounds sterling for price year 2012/13.  The basecase analysis 
does not incorporate additional research and start-up costs.   
INSERT TABLES 1 & 2 NEAR HERE 
Lifetime analysis 
A health economic model we previously developed (36;37) was adapted to incorporate the trial 
information, capturing the short and longer-term costs and health gains of cessation for the 
mother2.  The model uses a Markov design to simulate the lifetime likelihood and impact of 
cessation, expressing the long-term health benefits of quitting smoking in terms of QALYs and the 
potential long-term reduction in costs to the health service of cessation.  The model accounts for any 
relapse to smoking post-trial; in the six month period following birth, and for up to eight years post-
quit (which will have cost and life expectancy impacts in the long term). Post-birth hospitalisation 
costs for premature and low birth weight babies were included, and long-term cost of treating 
smoking related diseases was incorporated in a scenario analysis. 
INSERT FIGURE 1 NEAR HERE 
Figure 1 depicts the Markov model, which simulates the options for a cohort of pregnant smokers 
undertaking a quit attempt.  The model consists of four main Markov states that a smoker can move 
to once they undertake a quit attempt: Ex-smoker, Smoker (relapsed), Non Smoking Related Death 
and Smoking Related Death.  After a quit attempt, a woman will either be successful and become an 
ex-smoker, or relapse and remain a smoker. The direction of the arrows indicate possible transitions 
between the states. For example, ex-smokers who were successful in the quit attempt can still 
relapse later in life to become smokers again. It is assumed however that no further quit attempts 
are undertaken, so there is no transition from the smoker relapsed state to the smoker quit attempt 
or ex-smoker states.  Ex-smokers can remain an ex-smoker, relapse to become a smoker again, die 
                                                                 
2 As the phase II CPIT trial found no difference in low birth weight or premature births between study arms 
(33), the l ifetime economic modelling was undertaken only for the mothers.  
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from non-smoking related causes or die from smoking related causes.  Clients in the smoking relapse 
state remain here until they die from either a smoking or non-smoking related cause.   
The model begins with a cohort of 1000 pregnant smokers, with a mean age of 28 years (average age 
from the trial) and runs in annual cycles until the entire cohort has died. The model is run for the 
routine care arm and for the financial incentives arm over the patient lifetime to calculate the mean 
cost, life expectancy and QALYs for each cohort. The first year of the model includes the arm specific 
trial costs and outcomes (up to 38 weeks pregnancy), followed by a six month post-trial period to 
allow for post-birth hospital costs for low birth weight babies and possible smoking relapse in 
mothers. Table 3 details the model input parameters and their sources, including standard errors 
and the distribution used in the probabilistic analysis.  Costs and outcomes incurred beyond the first 
year were discounted at 3.5% as per recommended guidelines (24). Further details of the model, 
parameters, probabilistic analysis and assumptions are provided in the supplementary report. 
INSERT TABLE 3 NEAR HERE 
Sensitivity analyses 
The model was analysed probabilistically (30;40) using a 1000 iteration Monte Carlo simulation to 
characterise uncertainty in the input parameters, and estimate confidence limits around the cost 
and effectiveness outcomes.  Table 3 details the standard errors and distributions for the 
probabilistic analysis.  An expected value of perfect information (EVPI) analysis (41;42) was carried 
out assuming an eligible population of 31,330 pregnant smokers in the UK per annum who would be 
referred to specialist smoking cessation services (9) over a conservatively assumed intervention 
lifetime of five years, discounted at 3.5%. 
The model was re-run under six alternative scenario analyses to explore the impact of varying some 
of the assumptions using (1) the self-reported 6- month postnatal relapse rates (12 months post 
quit)followed-up post trial , (2) a worst case assumption on postnatal relapse (80% for the Incentives 
arm), (3) incorporating a cost for future smoking related disease, (4) no discounting, (5) adjusting the 
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analysis to account for gaming that was evidenced in the trial), (6) the trial self-reported quit rates at 
34-38weeks as opposed to cotinine validated quit rates.  
Finally, the amount of incentive and the corresponding impact on size of effect was considered in 
sensitivity analysis, given the growing evidence that substantially increasing incentive amount can 
impact on effect size from both the broader drug abstinence and smoking cessation fields 
(25)(43)(44). Scenarios 7 & 8 re-calculate cost-effectiveness using: (7) double the original incentive 
amount - a maximum of £800 vouchers (daily equivalent £4), (8) a maximum of £1800 vouchers 
(daily equivalent £10). Further information regarding the sensitivity analyses and evidence base are 
detailed in the supplementary report. 
RESULTS  
Table 4A and Figure 2 detail the base case outcomes.  
INSERT TABLE 4 NEAR HERE 
The within-trial analysis gave an incremental cost per late pregnancy quitter of £1127 compared to 
routine care. The lifetime model resulted in an incremental cost of £17 (95% CI: -£93, £107) ($263) 
and a gain of 0.04 QALYs (95% CI: -0.058, 0.145), giving an ICER of £482/QALY ($734/QALY).  These 
results are highly cost-effective and similar to cost-effectiveness ratios found for a range of smoking 
cessation interventions (45;46)(72).  Figure 2 shows the distribution of incremental cost and QALY 
outcomes from the probabilistic analysis on a cost-effectiveness plane. The majority of  values fall in 
the north eastern quadrant, with an ICER of £482/QALY, well below the UK threshold of 
£20,000/QALY (30). However,  uncertainty is present– primarily due to  relapse rates post trial- 
which is demonstrated in Figure 2 where outcomes pass through the origin into all four quadrants. 
INSERT FIGURE 2 NEAR HERE 
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The cost-effectiveness acceptability of the Incentives in comparison to the Control was calculated 
over a range of willingness to pay thresholds. At a willingness to pay of £20,000 to £30,000/QALY, 
Incentives had a 72% likelihood of being cost-effective compared to the Control. The probability of 
cost-effectiveness is detailed in Table 4B for the basecase and eight alternative scenario analyses. 
Table 4B shows the incentives arm is a highly cost-effective option over a range of alternative model 
assumptions. Only in the extreme worst case scenario 2 (assuming 80% relapse for Incentives, 30% 
relapse for Control post trial) was the control arm the optimal option, with a probability of 70%.   
Increasing the value of financial incentives offered is likely to be a cost-effective strategy as 
demonstrated in scenarios 7 & 8; however ICER values increase substantially compared to baseline, 
due to diminishing returns on the level of effect.  The EVPI analysis (figure 3) indicated that given 
current uncertainty, the value of further information is £30million. Therefore additional research to 
improve evidence on quit rates and  relapse rates post birth and post incentive is likely to be 
worthwhile.  
 
Discussion 
This economic evaluation has shown that financial incentives are highly likely to be cost-effective for 
pregnant smokers in encouraging engagement and successful cessation during pregnancy with 
existing stop smoking services.  Financial incentives in addition to routine care for pregnant women 
were found to be cost-effective at £482/QALY ($734/QALY)which is well below recommended cost-
effectiveness thresholds in high income countries (30;49;50). This is comparable to and in some 
cases lower than ICERs reported for more general smoking cessation interventions (45;46;51;52), 
particularly those for pregnancy (53-55) .  
The incremental cost per quitter outcomes from our analysis correspond with values from the 
standardised ICER tables for smoking cessation studies endorsed by Stapleton & West to promote 
consistency and comparability between smoking cessation studies (72). Looking-up the CPIT trial 
incremental cost (£157) and incremental 6 month quit outcome (0.14) in their published tables (72), 
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predicts an approximate ICER value of £1390 per quitter (72), a close similarity to our ICER of £1127 
per 34-38 week CO validated quitter.  
 
Considering the wider evidence base for financial incentives supporting abstinence from a range of 
different abused drugs (16;43) and for healthy behaviours in general (47) the positive findings from 
the CPIT Trial (33) are unsurprising (48), and this paper adds additional evidence regarding the cost-
effectiveness to support implementation in practice.  . Following a NICE guidelines report (19) which 
recommended implementation of incentives for community substance abuse treatment centres in 
the UK; this paper further supports the cost-effective case for implementation.  The basecase results 
for the economic analysis are highly encouraging; however, they are subject to uncertainty regarding 
post birth relapse, once the incentive has stopped.   The uncertainty intervals around the mean cost 
and QALY outcomes in Table 4A, and Figure 2 demonstrate the extent of this uncertainty. .  The trial 
did not incorporate follow-up beyond birth and only self-reported quit rates at 6 months postpartum 
were available. These relapse rates were encouraging:33% relapse for Incentives and 54% in the 
Control respectively(32), but without CO validation they are potentially biased, particularly for the 
Incentives arm where women may feel obliged to report a sustained quit post-trial.  Therefore, 
literature on CO validated quits post-partum was consulted (20; 64) (56)(26), and a conservative 
approach adopted, assuming post-birth relapse rates which favoured the Control arm(60% relapse 
for Incentives,  30% relapse in the Control, as detailed in Table 3) (26)(64). Scenario 1 of the 
sensitivity analyses reports outcomes when we adopt the post-trial self-reported rates, giving an 
improved ICER of £164/QALY ($250/QALY) and a 99% probability that Incentives are the cost-
effective option.  In future trials, CO-validated evidence post-birth and post incentive would be 
beneficial and strengthen the evidence base.  A future trial which  measured longer-term relapse 
rates  could also explore the cost-effectiveness of  financial incentive for relapse prevention post 
birth, given the demonstrated success of financial incentives in the short term. 
 
11 
 
arms (34)(28) 
 
A possible unintended consequence of financial incentives is the possibility of ‘gaming’; whereby 
women could be untruthful about their smoking status, especially at the time of the primary 
outcome assessment where  50% of the incentive is offered. The CPIT and economic analysis tested 
for this type of ‘gaming’ (33)  and found approximately 20% of women were untruthful about their 
smoking status, in both arms. This is higher than a recent single arm study on financial incentives in 
England, which found only 4% of participants gamed to gain cessation vouchers  (26). Scenario 5 of 
our sensitivity analysis (Table 4B) adjusted for gaming (adjusting quit rates to exclude gamers, but 
keeping the costs incurred by them) and found incentives remained cost-effective, but with an 
increased ICER of £1443/QALY ($2198/QALY). This ICER remains well below the thresholds in high 
income countries (24;39;40), so even accounting for gaming, would be considered cost-effective.  
 
Many high income countries offer a variety of specialist cessation interventions during pregnancy 
(1;2;6;49;50) yet in the UK only 25% of pregnant women make a quit attempt, and only 8% have 
been found to (via self-report) quit(58).  The CPIT trial found a significant increase in quit when 
offered Incentives(22.5%) than Control (8.6%), a cessation improvement that is larger than that seen 
in most behavioural, (59) or pharmaceutical (60) pregnancy cessation trials. Previous systematic 
reviews of varied intervention strategies (59) highlight that current recommendations to help 
smokers quit during pregnancy (11) are not very effective.  There is a growing evidence base 
showing financial incentives to have positive effects on health behaviours (11;13)(15-19), particularly 
in the smoking cessation arena (20,21).  Likis et al. (61) recently reported that out of a range of 
interventions for smoking cessation during pregnancy, financial incentives demonstrated the 
strongest effect. Despite this evidence base, few studies have considered the cost-effectiveness of 
financial incentives, and none have assessed this for smoking cessation during pregnancy. If financial 
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incentives to aid smoking cessation are to be considered as an option in high income countries, then 
economic analyses are essential to policy-making considerations.   
 
Policy Implications 
Identifying pregnant women who smoke, engaging with them and supporting them to quit smoking 
during pregnancy is a key international tobacco policy priority  (11;62) and this study provides 
evidence on the cost-effectiveness of financial incentives as a means to achieving cessation during 
pregnancy. 
 
Godfrey et al. (3) found the cost of smoking during pregnancy is £8 - £64 million per annum 
($367million (4) in the USA). They estimate that low cost cessation interventions (costing between 
£13 and £37 per pregnant smoker) could yield positive cost savings, but recommend further 
research on enhanced investment in smoking cessation interventions. Our sensitivity analysis 
(scenarios 7 & 8) show that enhanced incentives offering up to £800 and £1800 per quitter could 
potentially be cost-effective, while the base case analysis on the CPIT trial (33) provides evidence 
that financial incentives up to £400 in addition to routine care are a highly cost-effective way to 
encourage quit attempts and achieve cessation in pregnancy.  
This research paper provides economic evidence based on a phase II RCT to support the use of 
financial incentives in addition to routine smoking cessation services for pregnant women. Our 
findings address the gap in cost-effectiveness evidence (10) (11), showing financial incentives are a 
potentially cost-effective way to help women who smoke to engage with cessation services, and quit 
when they are pregnant.  
 
Strengths and weaknesses 
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The key strengths of this study are the RCT design and cost-effectiveness analysis.  The resource use 
and outcome data was informed from an RCT, and to our knowledge this is the first cost-
effectiveness analysis of financial incentives for pregnant smokers.  
Key limitations are in the exploratory (phase II) nature of the trial, in that it was limited to one 
geographical location in Glasgow, Scotland. This sample is potentially representative of large city 
populations; however, routine cessation services for pregnant women vary throughout the UK..  
Another limitation relates to the uncertainty of the data on relapse post birth (once financial 
incentives have stopped). The self-report postnatal data following the CPIT trial was encouraging, 
however, it could be subject to intervention group bias.  If these findings remained the same in a 
cotinine validated follow-up, then the QALYs difference between the trial arms is likely to be real. 
However, given current uncertainty, the expected value of perfect information analysis showed that 
it is worthwhile to undertake further research.  
This work strengthens the evidence base on potential cost-effectiveness of financial incentives and 
thus is extremely valuable for policy makers, both in the UK and in other high income countries in 
Europe and the USA.  
CONCLUSION 
Existing interventions for pregnant smokers are not highly effective; however, this study provides 
substantial evidence on the cost-effectiveness of a financial incentives intervention to add to existing 
cessation support. This study shows financial incentives to be highly cost-effective with an 
incremental cost-effectiveness ratio (ICER) of £482/QALY ($734/QALY) which is well below 
recommended thresholds.  
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WHAT THIS PAPER ADDS 
• This is the first cost-effectiveness analysis of financial incentives for smoking cessation in 
pregnant women  
• This study shows that financial incentives are highly likely to be cost-effective 
• CO validated evidence regarding sustained quit once the incentive has ended and relapse post 
birth is needed to strengthen the evidence base. 
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Tables & Figures 
Table 1: Resource Use Information 
Resource     Incentives Control 
Vouchers        Number* Number* 
Vouchers postage & packaging     504 NA 
Additional vouchers re-posted      30 NA 
1st Incentive: 1st face to face contact £50     248 NA 
2nd incentive: 4 wks post quit £50     96 NA 
3rd Incentive: 12 weeks post quit £100     79 NA 
4th Incentive: 34-38 wks £200 CO validated    81 NA 
Cessation Support Duration 
std 
error Number* Number* 
1st phone contact (minutes) 10.00 5.10 210 225 
1st face-face support (minutes) 50.00 15.31 248 236 
1st post quit-date phone call only (minutes) 15.00 7.65 1 1 
1st & 2nd post quit-date phone calls 15.00 7.65 3 7 
1st, 2nd & 3rd post quit-date phone calls 15.00 7.65 9 26 
1st, 2nd 3rd & 4th post quit-date phone calls 15.00 7.65 21 38 
1st, 2nd, 3rd, 4th & 5th post quit-date calls 15.00 7.65 212 160 
Unknown (assume mean 4.8 calls)†   5 6 
Unknown (assume no calls)††     55 68 
          
Nicotine Replacement Therapy     Number* Number* 
NRT 4 week prescription wk 1     158 155 
NRT 4 week prescription wk 5     61 38 
NRT 4 week prescription wk 10     32 15 
          
*Number of participants in each arm of CPIT trial receiving which resources 
 †attended 1st face to face meeting – assume mean 4.8 calls 
 †† did not attend 1st face to face meeting – assume zero post quit date calls 
 
 
Table 2: Unit Cost Information 
Cost Area Unit Costs Source 
Smokefree Pregnancy advisor (Band 5) cost per hour £35.00 Curtis, L 2013 
NRT: Nicorette 16hr patch (1st line) cost per week £9.97 BNF 2013  
Low Birth weight: Special Care Baby Unit cost per case £8,602.00 ISD,  2012  
Vouchers postage & packaging £7.48 CPIT trial 
Additional vouchers re-posted (postage only 2013)  £7.46 CPIT trial 
1st Incentive: 1st face to face contact £50 £50.00 CPIT trial 
2nd incentive: 4 wks post quit £50 £50.00 CPIT trial 
3rd Incentive: 12 weeks post quit £100 £100.00 CPIT trial 
4th Incentive: CO validated 34-38 wks £200  £200.00 CPIT trial 
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Table 3: Lifetime Model parameter inputs 
Parameters Value std error distribution source 
Trial Outcomes     
34-38week quit Incentive (cotinine validated) 0.225 0.0239 beta (33)  
34-38week quit Control (cotinine validated) 0.086 0.0161 beta (33)  
P very low & low birth weight  - quitters 0.03 0.0180 beta (33)  
P very low & low birth weight  - smokers 0.15 0.0156 beta (33)  
Cessation Support     
Duration 1st phone call (mins) 10.00 5.1020 gamma (33)  
Duration 1st face–to-face support (mins) 50.00 15.3061 gamma (33)  
Duration post quit date phone calls (mins)  15.00 7.6531 gamma (33)  
Relapse Rates     
P Relapse 3 months post birth Incentive 0.60 0.1800 beta (20;26)  
P Relapse 3 months post birth Control 0.30 0.0600 beta (64),AA 
Annual P Relapse yrs 1-5 post quit 0.05 NA NA (65) 
Annual P Relapse yrs 6-8 post quit 0.03 NA NA (65) 
Unit Costs     
NRT, 1st line (cost/week) £9.97 NA NA (66) 
Smokefree Pregnancy advisor (cost/hr) £35.00 NA NA (39) 
Incentive voucher postage & packaging £7.48 NA NA (33)  
Incentive voucher 1st & 2nd  £50.00 NA NA (33)  
Incentive voucher 3rd £100.00 NA NA (33)  
Incentive voucher 4th £200.00 NA NA (33)  
NHS cost for low & very low birth weight†  £8,602 £1,720 gamma (67) 
Cost smoking related disease - basecase £0 £0 NA AA 
Cost smoking related disease†† - scenario £32,658 £6,532 gamma (68) 
Mortality rates     
Scottish female smoking related mortality** mortality tables NA (69;70)  
Scottish female mortality excluding smoking** mortality tables NA (69;70)  
Utilities     
female smoker age 25-34 0.92 0.0024 beta (71) 
female smoker age 35-44 0.89 0.0027 beta (71) 
female smoker age 45-54 0.78 0.0043 beta (71) 
female smoker age 55-64 0.69 0.0048 beta (71) 
female smoker age 65-74 0.75 0.0051 beta (71) 
female smoker age 75+ 0.67 0.0051 beta (71) 
female non smoker age 25-34 0.93 0.0027 beta (71) 
female non smoker age 35-44 0.92 0.0024 beta (71) 
female non smoker age 45-54 0.87 0.0036 beta (71) 
female non smoker age 55-64 0.82 0.0041 beta (71) 
female non smoker age 65-74 0.78 0.0043 beta (71) 
female non smoker age 75+ 0.72 0.0045 beta (30;71)  
Discount Rate     
outcomes & costs (beyond yr 1)  0.035 NA  (24) 
P=probabili ty, AA = Author assumption 
 
 
*Scenario analysis 1 uses self-reported 3 month relapse rates ; † Mean cost Special Care Baby Unit, inpatient cost per case 
†† Scenario Analysis 3: mean cost £32,658 per smoking related death   
**Lifetables  for Scottish Females, age adjusted population death rates per 1000   
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Table 4: 4A - Basecase analysis results, 4B - Scenario analyses results 
  Table 4A   Mean Mean Incremental Incremental  Incremental cost-
effectiveness ratio (ICER)   Economic Analysis Arm Cost effect  Cost effect 
    quit  quit   
  Within trial   Control £85 0.09 £157 0.14     
  (incremental cost per quitter) Incentives £243 0.23 (£155, £162) (0.08, 0.19)  £1,127 per quitter 
     QALY  QALY     
  Lifetime Control £1,265 19.101 17 0.036     
  (incremental cost per QALY) Incentives £1,282 19.137 (-£93, £107) (-0.058, 0.145) £482 per QALY 
  Table 4B   Mean Mean Incremental Incremental   Prob CE 
  Scenario Analyses Arm Cost QALYs  Cost QALYs ICER £30K/Q* 
  Base-case analysis Control £1,265 19.10         
   Incentives £1,282 19.14 £17 0.036 £482 0.72 
1 Self-reported postnatal relapse Control £1,245 19.08 £21 0.13 £164 0.99 
  Incentives 33%, Control 54% Incentives £1,267 19.21 (-£87, £101)  (0.018, 0.228)      
2 Incentive arm higher Postnatal Control £1,257 19.10 £20 -0.017 Usual Care 0.30 
   Risk Relapse (80%, se 0.18) Incentives £1,277 19.09 (-£101, £99) (-0.092, 0.15)  Dominates   
3 Include cost for  Control £25,397 19.10         
  smoking related disease Incentives £24,820 19.14 -£577 0.039 Incentives 0.73 
  (£32,658, se £6532)        (-£2382, £821) (-0.05, 0.15) Dominates   
4 Discount rate 0% Control £1,254 40.02 £20 0.117 £167 0.75 
    Incentives £1,274 40.14 (-£90, £100) (-0.187, 0.459)     
5 Gaming: exclude 20% quitters Control £1,273 19.09         
  Probability 34-38 week quit:  Incentives £1,320 19.12 £47 0.033 £1,443 0.74 
   Incentives 18%, Control 7%       (-£47, £111) (-0.036, 0.121)     
6 Use self reported quit rates Control £1,137 19.21     Incentives   
  Probability quit 34-38 weeks: Incentives £1,121 19.21 -£16 0.003 Dominates 0.49 
   Incentives 39%, Control 21%       (-£153, £86) (-0.14, 0.196)      
7 Increase incentive max £800 Control £1,256 19.10 £152 0.062 £2461 0.64 
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  Prob quit 34-38 week: 0.28:  Incentives £1,408 19.16 (£81, £538)  (-0.03, 0.184)      
8 Increase incentive max £1800 Control £1,256 19.10 £579 0.133 £4360 0.59 
  Prob quit 34-38 week: 0.43:  Incentives £1,835 19.23 (£236, £982) (-0.04, 0.362)      
* probability that Incentives Arm is cost-effective at a threshold of £30,000/QALY       
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Figure 1: Markov Model 
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Figure 2: Cost-effectiveness plane – Financial Incentives versus Control 
 
 
 
Figure 3: Expected Value of Perfect Information – population level 
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